

Sandra Jesus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9103241/publications.pdf>

Version: 2024-02-01

22
papers

646
citations

706676

14
h-index

759306

22
g-index

22
all docs

22
docs citations

22
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles—Effects of Polymer Molecular Weight, Hydrolysis, and Blends. <i>Chemical Research in Toxicology</i> , 2020, 33, 2819-2833.	1.7	7
2	Chitosan Nanoparticles: Shedding Light on Immunotoxicity and Hemocompatibility. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 100.	2.0	57
3	Safe-by-Design of Glucan Nanoparticles: Size Matters When Assessing the Immunotoxicity. <i>Chemical Research in Toxicology</i> , 2020, 33, 915-932.	1.7	12
4	A Methodological Safe-by-Design Approach for the Development of Nanomedicines. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 258.	2.0	44
5	Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. <i>International Journal of Pharmaceutics</i> , 2020, 589, 119776.	2.6	64
6	Poly(D,L-Lactic Acid) Nanoparticle Size Reduction Increases Its Immunotoxicity. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 137.	2.0	35
7	Optimization of Chitosan- β -casein Nanoparticles for Improved Gene Delivery: Characterization, Stability, and Transfection Efficiency. <i>AAPS PharmSciTech</i> , 2019, 20, 132.	1.5	15
8	Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. <i>Pharmaceutics</i> , 2019, 11, 72.	2.0	29
9	Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 261.	2.0	62
10	The Inclusion of Chitosan in Poly- ϵ -caprolactone Nanoparticles: Impact on the Delivery System Characteristics and on the Adsorbed Ovalbumin Secondary Structure. <i>AAPS PharmSciTech</i> , 2018, 19, 101-113.	1.5	13
11	Adjuvant Activity of Poly- ϵ -caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN- γ and IL-17 Production. <i>Molecular Pharmaceutics</i> , 2018, 15, 72-82.	2.3	28
12	Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming. <i>International Journal of Pharmaceutics</i> , 2018, 535, 261-271.	2.6	37
13	Exosomes as adjuvants for the recombinant hepatitis B antigen: First report. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 1-11.	2.0	39
14	Chitosan- β -glucan particles as a new adjuvant for the hepatitis B antigen. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 131, 33-43.	2.0	23
15	Poly- ϵ -caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. <i>Nanomedicine</i> , 2017, 12, 2335-2348.	1.7	29
16	Poly- ϵ -caprolactone/Chitosan and Chitosan Particles: Two Recombinant Antigen Delivery Systems for Intranasal Vaccination. <i>Methods in Molecular Biology</i> , 2016, 1404, 697-713.	0.4	11
17	Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly- ϵ -caprolactone based nanoparticles. <i>International Journal of Pharmaceutics</i> , 2016, 504, 59-69.	2.6	41
18	Sonication-Assisted Layer-by-Layer Assembly for Low Solubility Drug Nanoformulation. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 11972-11983.	4.0	43

#	ARTICLE	IF	CITATIONS
19	Synthesis and controlled curcumin supramolecular complex release from pH-sensitive modified gum-arabic-based hydrogels. RSC Advances, 2015, 5, 94519-94533.	1.7	33
20	Freeze Dried Chitosan/ Poly- $\hat{\mu}$ -Caprolactone and Poly- $\hat{\mu}$ -Caprolactone Nanoparticles: Evaluation of their Potential as DNA and Antigen Delivery Systems. Journal of Genetic Syndromes & Gene Therapy, 2013, 4, .	0.2	6
21	Chitosan-Based Nanoparticles as a Hepatitis B Antigen Delivery System. Methods in Enzymology, 2012, 509, 127-142.	0.4	12
22	Recent Developments in the Nasal Immunization against Anthrax. World Journal of Vaccines, 2011, 01, 79-91.	0.8	6